Idiopathic Pulmonary Fibrosis Clinical Trials

74 recruitingLast updated: June 17, 2026

There are 74 actively recruiting idiopathic pulmonary fibrosis clinical trials across 49 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include Kansas City, Kansas, United States, Birmingham, Alabama, United States, Philadelphia, Pennsylvania, United States. Updated daily from ClinicalTrials.gov.


Idiopathic Pulmonary Fibrosis Trials at a Glance

74 actively recruiting trials for idiopathic pulmonary fibrosis are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 24 trials, with the heaviest enrollment activity in Kansas City, Birmingham, and Philadelphia. Lead sponsors running idiopathic pulmonary fibrosis studies include Avalyn Pharma Inc., Boehringer Ingelheim, and Hospital de Granollers.

Browse idiopathic pulmonary fibrosis trials by phase

Treatments under study

About Idiopathic Pulmonary Fibrosis Clinical Trials

Looking for clinical trials for Idiopathic Pulmonary Fibrosis? There are currently 56 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Idiopathic Pulmonary Fibrosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Idiopathic Pulmonary Fibrosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 74 trials

Recruiting
Phase 3

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis
Boehringer Ingelheim1,700 enrolled373 locationsNCT06238622
Recruiting
Phase 2

Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Contineum Therapeutics324 enrolled22 locationsNCT07284459
Recruiting
Phase 2

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Mediar Therapeutics164 enrolled69 locationsNCT06967805
Recruiting
Phase 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim71 enrolled46 locationsNCT07036523
Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

SarcoidosisIdiopathic Pulmonary FibrosisInterstitial Lung Diseases+1 more
University of Chicago4,000 enrolled1 locationNCT00470327
Recruiting
Phase 2

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics120 enrolled16 locationsNCT06968845
Recruiting
Phase 1

Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
University of Alabama at Birmingham10 enrolled1 locationNCT04362644
Recruiting
Not Applicable

Skeletal Muscle Function in Interstitial Lung Disease

Interstitial Lung DiseaseIdiopathic Pulmonary FibrosisScleroderma+2 more
University of British Columbia40 enrolled1 locationNCT03800017
Recruiting
Phase 1

A Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants

Idiopathic Pulmonary Fibrosis
Endeavor Biomedicines, Inc.57 enrolled2 locationsNCT07454291
Recruiting
Not Applicable

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
Assiut University1,000 enrolled2 locationsNCT05842681
Recruiting
Phase 2

Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Dragonboat Biopharmaceutical Company Limited96 enrolled1 locationNCT07447102
Recruiting
Phase 2

Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease

Idiopathic Pulmonary FibrosisPulmonary Fibrosis, Interstitial Lung Disease
Vejle Hospital140 enrolled5 locationsNCT06714123
Recruiting

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Duke University3,000 enrolled44 locationsNCT01915511
Recruiting
Phase 1

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis (IPF)
Mannkind Corporation24 enrolled9 locationsNCT07344558
Recruiting
Phase 2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim20 enrolled3 locationsNCT06241560
Recruiting
Phase 2

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

Progressive Pulmonary FibrosisIdiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.340 enrolled52 locationsNCT06951217
Recruiting
Phase 3

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

Idiopathic Pulmonary Fibrosis (IPF)
Sunshine Lake Pharma Co., Ltd.472 enrolled1 locationNCT07082842
Recruiting
Phase 1

NAL ER IPF Respiratory Function and Safety Study

Idiopathic Pulmonary Fibrosis
Trevi Therapeutics10 enrolled2 locationsNCT07036029
Recruiting
Phase 2

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis
AbbVie165 enrolled6 locationsNCT07230288
Recruiting
Not Applicable

Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

Fibrotic interstitial lung diseaseInterstitial Lung Disease (ILD)Idiopathic Pulmonary Fibrosis (IPF)+2 more
Hospital de Granollers92 enrolled1 locationNCT07482917